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Abstract
　The purpose of this article is to reveal the impact of external factors on intellectual 
property (IP) strategy by focusing on how institutional transitions matter for IP strategy 
from historical perspective. The paper will challenge to analyze the issue of how institutional 
transitions matter for strategic choices in the Japanese pharmaceutical industry during the 
period of 1970-2017. Highlighting the changes in foreign investment regulation and patent 
system, it reveals the facts of how institutional transitions impact the corporate ownership 
and subsequent strategies.
　This study shows that changes in foreign investment regulation and patent system 
progress the globalization in the Japanese pharmaceutical industry, thus triggering the 
transitions of IP strategy. Institutional transitions lead the IP strategy from imitative to 
innovative for improving international competitiveness. In addition, this innovative IP 
strategy was developed from scale advantage perspective to resource-based perspective 
because of increasing R&D cost year after year under institutional pressures.
Keyword:  institutional transitions, external factors, research and development (R&D), 
pharmaceutical, ownership, patent system, innovation
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1. Introduction
　The purpose of this paper is to reveal the impact of external factors on the intellectual 
property (IP) strategy of pharmaceuticals, and particularly, to focus on the changes in 
institutions from a historical perspective.
　What determines the IP strategy of pharmaceuticals? IP strategy is defined here as the 
way through which companies create or obtain IP and what role this plays in the 
enrichment of drug discovery pipelines. The pharmaceutical industry requires to remain the 
level and productivity of R&D (Research and Development) spending. Such activity requires 
sufficiently high profits, and the ability to secure external financing. However, a challenge 
that pharmaceutical companies have been exposed to since the mid-1990s is a decline in 
R&D productivity, despite sustained increases in R&D expenditure. The continued increase 
in the cost of R&D is considered to be one of the driving forces behind the industry’s trend 
towards consolidation to retain competitive advantage. The pharmaceutical industry 
probably sees more merger and acquisition (M&A) activity than any other industry, both in 
the number of deals and the amount of money spent on M&A. M&A is seen as an effective 
way to resolve the issues causing the decline in R&D productivity that impact on its future 
competitiveness. 
　In reviewing representative literature on R&D profitability, economy theory, which 
focuses on scale and scope advantages (e.g., Langowitz and Graves, 1992; Henderson & 
Cockburn, 1996; Anagnostopoulou & Levis, 2008), may first become most relevant. Those 
studies have indicated that the greater the R&D expenditure, the greater the number of 
R&D products (e.g., Langowitz and Graves, 1992; Henderson & Cockburn, 1996; 
Anagnostopoulou & Levis, 2008). Henderson & Cockburn (1996), for example, suggested that 
with larger R&D scale and scope, a higher return will be generated due to the spillover 
advantage and internal spillover of knowledge. They found a positive association between 
the returns and R&D intensity; that is, because of the economies of scope and scale achieved 
by R&D, greater R&D efforts were more productive and less uncertain.
　And then, later on, resource-based theory (e.g., Danzon et al., 2005; Mait & Raghavendra, 
2007; Lowman et al., 2012; Rafols et al., 2014; Paul et al., 2010), which centres on firm-specific 
capabilities, is likely to be more relevant. Some research has proposed that the utilisation of 
external resources, and the rationalisation of portfolios will improve profitability from the 
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cost reduction perspective, since the way of utilising external resources has the following 
strengths: cost reduction, reduction of the time-to-market, and risk distribution (e.g., Danzon 
et al., 2005; Mait & Raghavendra, 2007; Lowman et al., 2012; Rafols et al., 2014; Paul et al., 
2010). Utilising external resources, however, can not only reduce R&D costs and spread risk, 
but can help a company concentrate its resources on developing core yields. In order to 
access the external resources, pharmaceutical companies conduct M&A, as well as form 
strategic alliances with other companies that have high technologies in the specific field 
through licensing-in, collaborative research, and out-sourcing the clinical development 
process (Danzon et al., 2005; Mait & Raghavendra, 2007; Kneller, 2010; Howells et al., 2008; 
Howells et al., 2012; Lin et al., 2012). 
　As mentioned before, previous studies consider the IP strategy from the scale advantage 
perspective, and the resource-based perspective, but have not paid adequate attention to the 
institutions transition.     
　However, the issue of how organisations (firms) make strategic choices during 
fundamental institutional transitions, what lead IP strategies changes in the pharmaceutical 
remain largely unknown. This paper will attempt to analyse the issue of how institutional 
transition matters for strategic choices in the four leading Japanese pharmaceutical 
companies, during the period of 1970-2017. This paper addresses the following two issues. 
The first is to examine the factors that influence four companies’ IP strategies. The second 
is to reveal the IP strategies employed across time.
　The paper is organised in four parts. Section 2 provides an overview of the institutional 
transition and how it impacts the strategic choice, then develops a conceptual framework 
for analysing four leading Japanese pharmaceutical companies, which include: Takeda 
Pharmaceutical Company Limited, Eisai Co. Ltd., Daiichi Sankyo Company Limited, Astellas 
Pharma Inc. during the period of 1970-2017. Section 3 examines how the external 
environment impacts on IP strategy decisions by those four companies. This section also 
discusses the nature of the opportunities they exploit and the modes of operation they 
employ in each period. Finally, the final section concludes.
2. Literature Review- Institutional changes and strategic choices
　Institutions are typically conceptualised as “the rules of game in a society” (North, 1990; 
Scott, 1995), and institutional transitions can be defined as fundamental and comprehensive 
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changes introduced to the formal and informal rules of the game that affect organisations as 
players (North, 1990; Peng, 2003). North (1990) defines institutions as the “the humanly 
devised constraints”, which include formal rules (law, regulations) and informal constraints 
(customs, norms, cultures). 
　In response, organisations acquiesce to a variety of institutional pressures by making 
strategic choices (Child, 1972, 1997; Oliver, 1991, 1992). This strategic choice extends to the 
context within which the organization is operating, to the standards of performance against 
which the pressure of economic constraints has to be evaluated, and to the design of the 
organization’s structure itself as Child (1972: 2) points out.
　The role of institutions is to reduce uncertainty by establishing a stable (but not 
necessarily efficient) structure (North, 1990: 5-6). Therefore, an institutional transition can be 
conceptualised as a move from one primary mode of exchange to another mode (Peng, 2003: 
278). In other words, organisations may be required to reject old rules, learn new routines, 
and develop new capabilities, since conformity is useful to organisations in terms of 
enhancing organisations’ likelihood of survival (Oliver, 1991:150). 
　According to advanced research by D’ Aunno et al. (2000) and Newman (2000), the impacts 
of institutional transitions can be classified into two phenomenon, namely incremental and 
fundamental change. The first kind of change is also considered as divergent organisational 
change that occurs in a brief period (DiMaggio, 1983; Oliver, 1992; D’ Aunno et al., 2000, 
Newman, 2000). D’ Aunno et al. (2000) and Newman (2000) focus on fundamental change (or 
radical change), in which organisations abandon an institutional template for arranging their 
core activities, suggesting that fundamental change depends on both market forces 
(proximity to competitors) and institutional forces (state regulation, ownership and 
governance norms. The second change occurs when institutions evolve through a relatively 
long period of stability (Gersick, 1991; Peng, 2003).
　Who are the players in the progress of transition? Peng (2003: 283) notes that as the 
transitions progress, more new entrants join the game and organisational diversity 
increases, resulting in three major organisational forms, which are (1) incumbent firms, (2) 
entrepreneurial start-ups, and (3) foreign entrants. Scott (1995) states that during the 
transitions, different organisational forms are likely to confront different institutional 
pressures, thus leading to various strategic choices. Therefore, I highlight here the strategic 
choices of incumbent firms during the phases of transition in the Japanese pharmaceutical 
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industry. Incumbent firms used to be the central players prior to the transition, and their 
practices define institutional norms; however, the better the fit they have with the 
pretransition institutional context, the more difficult it is for them to successfully transform 
themselves (Peng, 2003: 285). 
Figure 1 Conceptual Framework
　Therefore, this paper will attempt to analyse the issue of institutional changes including 
formal and informal institutional change in the four companies. Special emphasis will be 
placed on how institutional changes (fundamental or incremental) impact on players in the 
progress of transition. Furthermore, the paper will analyse the issue on the basis of the 
following factors proposed by Oliver (1991). These are causes, constituents, control, and 
context. These will determine the choice of strategy, depending on why these pressures are 
being exerted, who is exerting them, what these pressures are, how or by what means they 
are exerted, and where they occur Oliver (1991: 159).
3. Institutional transitions in the Japanese pharmaceutical industry
　Some of the leading pharmaceutical companies have long histories of about 200 years. 
Most Japanese pharmaceutical companies started their business in Doshomachi1, which is 
located in Osaka, as wholesalers of traditional herbal medicine, and they did not undertake 
innovative activities (Yamashita, 2010)2. Japanese pharmaceutical companies, although 
1 　Doshomachi was a center for lapan’s pharmaceutica industry comprised 124 drugs brokerage companions 
that were recognised officially as fellow traders of stocks (thing which wholesale dealers gather, and put 
money paid to the authorities in the Shogunate, and monopolise authority of buying and selling) in the times 
of General Yashiro Yoshimune Tokugawa in 1722 by the Shogunate.
2 　Innovative activities are those which develop new chemical entities (NCEs) through extensive R&D 
programmes and market them as patented preparations.
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historically not as innovative as those in the United States and Western Europe, became 
strong competitors within decades primarily as a result of expanding globally. The pace and 
source of these transitions have varied dramatically since the late 1970s. What were the 
triggers for those changes? This paper examines the dramatic transformation of four 
leading Japanese R&D-driven pharmaceutical companies which mentioned above during the 
period of 1970-2017. While the Japanese pharmaceutical industry as a whole remained 
globally uncompetitive, the period of the 1970s saw divergent change for Japanese firms 
that shifted from being manufacturing-based to research-based for survival. The paper 
shows how firms respond to institutional changes, including fundamental and incremental 
institutional changes, and does so mainly through analysing the secondary data (industry 
reports, annual reports, newspapers, news releases). 
3.1 Fundamental change
　Two fundamental changes will be considered here. One is the Amendment of Patent Act 
of 1976, the other is the 100% capital liberalisation of the Japanese pharmaceutical industry 
that occurred in 1975. The patent system has had a significant effect on the development of 
pharmaceuticals; most importantly, it allows firms a period of market exclusivity in which 
they can partially recoup R&D expenditures. The Japanese Patent system3, however, had 
remained the weakest of the pharmaceutical industry before 1976. Prior to 1976, patents on 
pharmaceuticals had focused on the process, enabling pharmaceutical companies to produce 
new drugs that could be developed by foreign companies in different ways. Japanese firms 
were likely to depend on obtaining licences from foreign firms rather than developing their 
own products through innovation, as drug drug discovery and development is time-
consuming, expensive and unpredictable4.
　1976 marked the beginning of a new era that shifted the focus from process patents to 
3 　Japanese Patent System (not only pharmaceutical but all sectors) was weak before 1960s. Because during 
this period, Japanese companies had focused on learning and imitating the technologies that discovered by 
American and European companies, paying little attention to intellectual property right (Tanaka, 2011: 1150).
4 　Especially in the pharmaceutical industry which requires huge R&D expenditures to develop one new 
drug, and the huge cost always decreases the firm’s profit. It takes an average of 10-15 years to develop a 
new medicine, from the earliest stages of discovery to the time it is available for treating patients. The 
average cost to develop a drug increased from $179 million in 1970s, to 2.6 billion in 2010s (http://www.
phrma.org/sites/default/files/pdf/2015_phrma_profile.pdf Accessed Nov 18th 2019).
19-12-324　05　徐　玉琴（Yuqin Xu）.indd   116 2020/02/11   9:28:07
―　The linkage between institutional transitions and intellectual property (IP) strategies of pharmaceuticals: Japanese pharmaceutical industry, 1970-2017　― 117
ingredient patents5 on pharmaceuticals. The Japanese Patent Act was amended in 1976 and 
this had a fundamental impact on Japanese firms. The amendment of the Patent Act 
resulted in the fact that Japanese firms had to make a considerable commitment to R&D, 
both in terms of the size of their R&D budget and R&D staff to remain sales. The patent 
amendment in 1976 was also divergent change that decided firms’ future directions: 
operating as manufacturing-based or research-based. 
　The 100% capital liberalisation in 1975 had two critical influences on Japanese firms. 
Firstly, it varied the ownership structure and governance. Japanese capitalism has been 
characterised by the long-term relationships of firms with their employees (lifetime 
employment), other firms (keiretsu relationships6), and the government (state-industry 
relation). For example, Japanese firms have long maintained keiretsu relationships with 
other firms through cross-shareholding. The main shareholders are financial institutions and 
affiliated companies. These relationships, however, have gradually unravelled due to capital 
liberalisation since 19677. As result, the ownership structure of Japanese firms has also 
grown more diverse since the 1970s (Torii, 2017). As the ownership structure has an obvious 
impact on the likelihood of a change in corporate control, ownership composition has a 
primary influence on the need for such changes (Lichtenberg & Pushner, 1994: 244). The 
ownership structure constituted by cross-shareholding plays a critical role in deterring 
external takeovers, and the aim of governance was to pursue stabilisation of management 
through maintaining traditional long-term and stable business relations（Torii, 2017）. Since 
unravelled in stock cross-holdings, the ratio of foreign shareholding began to increase in the 
early 1990s, especially in larger firms8. As shown in Figure 2, the ratio of foreign 
5　A substance patent for the active ingredient of an approved drug product.
6 　Keiretsu with the governance ties of equity ownership, director transfers, and shacho-kai (presidents' 
council) membership is a structure of major company in Japan. Keiretsu network is composed by 
manufacturers, supply chain partners, distributers, and financiers who remain financially independent but 
work together to ensure each other’s success. Keiretsu networks can be classified into three types: 
horizontal keiretsu, which involve cross-holdings among companies centered on a bank; vertical keiretsu, 
which among a manufacturer and its suppliers; and compound keiretsu that involve features of horizontal 
and vertical types.
7 　According to Aramaki (2004: 57), the first phase of Japan’s liberalization was in July 1967, as regards 
inward direct investment, foreign.  
8 　In the case of the pharmaceutical industry, the government prohibited resale price maintenance (as apart 
of distribution reform) in pharmaceuticals in 1991, effectively dissolving the keiretsu relationships between 
select wholesalers and manufacturers (Inoue, 1990).
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shareholding has increased rapidly in four companies after capital liberalisation. Since 1970, 
the ratio of foreign shareholding in four companies exceeded the average of all industries, 
except Eisai during the period of 2010-2014. 
　The different ownership types lead to different forms of managerial outlook and mentality 
due to a number of macro and micro foundations giving rise to various managerial 
cognitions. The “voices” expressed by financial institutions and corporate shareholders differ 
from foreign institution investors. Financial institutions and corporate shareholders try to 
expand the long-term transactions9, while foreign institutional investors are concerned with 
rising stock prices and maximising shareholder value10 (Fukao, 1998). Foreign institutional 
investors pressure managers in order to improve shareholder value by voting (Torii, 2017). 
Under the pressure from foreign institutional investors, the situation of Japanese domestic 
markets has driven Japanese pharmaceutical companies to strengthen their operations in 
American and European markets. 
Note:  The DaiichiSakyo’s figures for 1970-2002 based on Daiichi. The Astellas’s figures for 1970-2002 based on 
Yamanouchi.
Source:  Japan Exchange Group, Yuka-shoken-hokokusho of each company mentioned above, various years 
(www.jpx.co.jp/markets/statistics-equities/examination/01.html Accessed Nov 18, 2019)
Figure 2 Transition in foreign stockholding ratio, 1970-2018 (%)
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9 　Previous studies show a common fact, that is lower profitability among group-affiliated firms. For 
example, Nakatani (1984) observed slower output growth and more stable performance among these firms, 
Caves and Uekusa (1976) found that profits were also negatively related to the share of equity held by 
group affiliates.
10 　Cable and Yasuki (1985) revealed that the concentration of shareholders outside the business group had 
a significant positive effect on profitability, but that concentration within the group did not matter.
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　Secondly, the 100% capital liberalisation greatly changed the business model of Japanese 
firms. Capital liberalisation decreased the level of competition that Japanese firms faced in 
the domestic market. In the era of deregulation, Japanese firms sold the drugs that 
produced foreign-discovered drugs under licence. For foreign firms, starting a market 
alliance with a Japanese firm is the best way to do business in the Japanese market because 
of foreign investment regulations. At the same time, this change promoted divergent change 
by increasing market competition. Foreign entrants adopted an entry strategy centred on 
wholly owned subsidiaries and acquisitions instead of taking market alliances with Japanese 
firms, due to the more aggressive market liberalisation. Capital liberalisation led to a rapid 
rise in the number of foreign firms operating in Japanese from 74 in 1970 to 239 by 1980 
(Umemura, 2013). This trend meant that Japanese firms were forced to find new sales 
drivers by themselves, and had to change their business model from imitative to innovative 
for survival. Between 1975 and 2016, the R&D expenditure in the Japanese pharmaceutical 
industry grew from 95.2 billion yen to 1,352 billion yen (JPMA, DATABOOK 2018). As a 
result, the number of drug patents by domestic firms increased from 376 in 1980, to 1,769 by 
2016 (JPMA, DATABOOK 2018).
　Therefore, capital liberalisation altered both governance norms and the business model of 
Japanese firms. Japanese firms (incumbents) having some foreign ownership may be more 
likely to initiate restructuring, because foreign investors may tolerate less inertia and have 
better access to resources that can facilitate restricting (Peng, 2003: 288). As foreign 
institutional investors’ definitions of effective performance become partially supplanted by 
corporate governance through voting rights, the institutional investors will increase the 
degree of control to the investing firm in order to maximise profits by voting. Unsatisfactory 
performance may push some incumbents to search for new competitive advantages 
(Filatotchev et al. 2000). 
　Capital liberalisation was a formal change; however, it also brought informal change which 
is norm of governance. Norms about governance are critical because they specify which 
actors, other than owners, will influence strategic decisions, such as those to engage in 
divergent change (Fligstein, 1996). Governance norms play an important part in promoting 
divergent organisational change because they specify how firms should be organised, 
including what roles superordinate authorities, such as boards, should play in decision-
making (Fligstein, 1996).
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　In summary, the amendment of the Patent act and 100% capital liberalisation11 were 
crucial determinants that led Japanese firms to alter their strategy from imitative to 
innovative in order to improve international competitiveness. There were divergent changes 
for Japanese firms caused by market competition and institutional factors. In other words, 
those institutional changes accelerated the globalisation of the Japanese pharmaceuticals 
industry.
3.2 Incremental change 
　Continued reform of drug price policy and US Food and Drug Administration (FDA)12 
regulations are considered here as incremental changes. In Japan, the prices of 
pharmaceutical products are set by the government and decline on a biennial basis13. The 
drug price policy of the Ministry of Health and Welfare (MHW), constrain the profits of 
Japanese firms; however, it is also a policy which can protect sales against the influences of 
generic after patent expired. At the same time, it was indicated that domestic companies 
faced pressure to enter foreign markets as a result of national policies to curb expenditure 
on pharmaceuticals14. 
　The globalisation of the Japanese pharmaceutical industry was a two-way street. Just as 
the number of foreign firms in the Japanese market grew, so the number of Japanese firms 
expanded overseas (Umemura, 2013). Between 1965 and 2016, the number of Japanese 
pharmaceutical companies expanding overseas grew from 10 to 372 (JPMA, DATABOOK 
2018). Hence, in addition to the regulation of the domestic market, Japanese firms have a 
11 　The Japanese government implemented these changes following Japan’s membership of the OECD and 
the World International Patent Organisation, under strong pressure from the United States, and based on 
its own desire to encourage technological development among Japanese firms (Umemura, 2013).
12 　The FDA is the institution that gathers evidence of the efficacy and safety of US food and drugs. The 
FDA plays an integral role in the use of pharmaceutical of pharmaceuticals, not only in the United States 
but worldwide. It has played an important role in shaping the modern, internal pharmaceutical industry by 
making the scientific approach and the clinical trial process the standard for establishing safety and 
efficacy.
13 　There has the National Health Insurance (NHI) Drug Price List, which is a list of drug prices to be 
reimbursed to hospitals and pharmacies under the national health insurance programs. Drug prices listed 
in the NHI Price list are periodically reviewed and revised to reflect actual trade prices based on market 
survey results. Once the drug which is listed in the NHI price list, this drug’s price will not be affected by 
generic even patent expired.
14　United States International Trade Commission, 1991:11.
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duty to conform to the regulations of foreign countries when they advance into overseas 
markets. The FDA, for example, requires data to demonstrate the safety of the product 
under consideration, so Japanese firms need to conduct a lot of testing to satisfy the FDA 
review while expanding into the US market which is the largest market in the world. The 
Kefauver-Harris amendment in 1962, total testing and FDA review increased, on average, 
from three to 10 years, given the increased emphasis on safety and efficacy15. During this 
period, the scale of R&D expenditure was considered to be one of the main driving forces16.
　Although the two-system drug price policy and FDA regulation vary in terms of 
procedures and purposes, the basic effect is to increase the R&D cost of pharmaceutical 
products. 
3.3 Historical transition of IP strategies
　How did firms respond to fundamental and incremental institutional changes? Although 
Oliver (1991) proposes five types of strategic responses, including acquiescence, compromise, 
avoidance, defiance, and manipulation17, Japanese firms commonly accede to institutional 
pressures by acquiescence.
　This research focus on IP strategy employed by four companies since 1970s. It should be 
emphasised that Table 1 is not a representation of the overall but is limited to the period of 
1970-2017. Changing IP strategy was stimulated by the loosening of protectionism from the 
late 1970s. Protectionism, which blocked foreign direct investment, led to stable 
management. The phenomenon was intensified by the patent system and foreign investment 
regulation. 
Table 1　Historical transition framework
1970~1975 1976-2005 2005~2016 2016-2017
imitative strategy in-house strategy open-innovation strategy co-innovation strategy
　Takeda was founded in 1781. In fiscal year 2017, its gross income was JPY1,770,531 million, 
with an operating income of JPY241,789 million. It invested about JPY 325,441million in R&D 
15 United States International Trade Commission, 1991: 8.
16 United States International Trade Commission, 1991 :4.
17 For further details on the five strategic responses, see Oliver (1991:151-158).
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in 2017, and in total has 27,230 employees.
　Astellas Pharma Inc. was created through a merger of Yamanouchi Pharmaceutical Co., 
Ltd. and Fujisawa Pharmaceutical Co., Ltd. on 1 April 2005. In fiscal year 2017, its gross 
income was　JPY1,300,316 million, with an operating income of JPY213,258 million. It has 
invested about JPY213,258 million in R&D in 2017. Astellas employs 16,617 staff worldwide.
　Daiichi Sankyo was established through the merger of Sankyo Company, Limited and 
Daiichi Pharmaceutical Company, Limited in 2005. In 2017, Daiichi Sankyo’s gross income 
was JPY960,195 million, and its operating income was JPY76,282 million. It invested 
JPY236,046 million in R&D 2017. It has 14,446 employees over 22 countries. 
　Eisai was established in 1942, had 10,456 employees in 2017, in which year gross income 
was JPY600,054 million, and its R&D expenditure was JPY 117,213 million. 
　Our four target companies have some common characteristics and differences. Firstly, 
they all had conservative IP strategies until the 1970s, although their operations were global. 
However, as Table 2 indicates, compared to Takeda, Daiichi Sankyo, Astellas, Eisai has been 
starting basic research earlier than other three companies, as Eisai started up as an 
innovative maker. Takeda started its business selling traditional Japanese and Chinese 
medicines in Doshomachi, Osaka. By contrast, the antecedent companies of Astellas and 
Daiichi Sankyo started its business importing drug. Four company had focused on importing 
business until 1950, in which year import exchange allocation system was introduced. Under 
this circumstance, they began to sell the drugs that produced foreign-discovered under 
license (Yamashita, 2010).  
　Secondly, they had shifted their IP strategy from in-house strategy, open-innovation 
strategy, then to co-innovation strategy (see Table 2). They engage in utilizing external 
resource mainly through M&A, outsourcing, license-in and cooperation. Compared to 
Takeda, Astellas, Daiichi Sankyo and Eisai, do not engage in M&A due to restriction of 
financial nature and lack of global management skill. Since 2016, they share the R&D 
candidate and pipeline with competitors in order to improve the output of R&D. 
19-12-324　05　徐　玉琴（Yuqin Xu）.indd   122 2020/02/11   9:28:07
―　The linkage between institutional transitions and intellectual property (IP) strategies of pharmaceuticals: Japanese pharmaceutical industry, 1970-2017　― 123
Table 2 Transition in Strategic choice by four companies
1970~1979 1979-2005 2005~2016 2016-2017
Takeda
・ take marketing li-
cense with foreign 
firms
・ focused on process 
patent
・ lack of basic re -
search
・1781 established
・in-house policy
・ marketing license 
with foreign firm
・ 1993 global opera-
tions
open-innovation poli-
cy
・M&A
・outsourcing
・license-in
co-creation policy
・ share resource with 
competitor
・M&A
・outsourcing
・license-in
・alliance with other
DaiichiSankyo
・2005 established
・in-house policy
・ 2000 global opera-
tions
co-creation policy
・ share resource with 
competitor
・outsourcing
・license-in
・ alliance with other 
fields
Astellas
・2005 established
・in-house policy
・ 1993 global opera-
tions open-innovation poli-
cy
・outsourcing
・license-inEsai
・ take marketing li-
cense with foreign 
firms
・ focused on process 
patent and basic re-
search
・1941 established
・in-house policy
・ 1997 global opera-
tions
Source: Based on annual reports of each company mentioned above.
　 In summary, prior to Patent System reform, Japanese companies obtained licences from 
US and European companies, thereby gaining access to new products. Japanese firms had 
depended on licensing foreign patented medicines rather than developing their own 
products through innovation during this period. Since the Japanese domestic pharmaceutical 
market was protected, they did not sufficient to build a strong R&D capability for competing 
on a global basis18. Consequently, it had not developed an R&D infrastructure that was 
comparable to that of stronger and more innovative industries such as those in the United 
States and some Western European countries19. By contrast, the US pharmaceutical industry 
had invested extensively throughout the world. During the 1940-80s, US firms accounted for 
about 62 percent of the new drugs introduced, Western European firms for about 27 
percent, and Japanese firms for about 2 percent20. The pharmaceutical industry requires 
access to a highly developed research base to develop innovative pharmaceutical products 
and improve R&D productivity.
18　United States International Trade Commission, 1991.
19　United States International Trade Commission, 1991: 3.
20　Pharmaceutical Manufacturers Association 1989:19.
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　Facing external, international demands, the Japanese investment regulation and patent 
system initiated major policy reforms. As a result, market competition dramatically 
intensified. After reform of the patent system and capital liberalisation, foreign companies 
invested directly instead of by contractual arrangement. Japanese firms faced the pressure 
to enter foreign markets, and to compete with foreign firms in the domestic market. The 
report indicates that of the 20 or so US firms that operated in Japan, 13 had wholly owned 
subsidiaries and eight had majority owned subsidiaries in 199121. The only way for Japanese 
companies to survive the international competition was to improve their R&D capability. 
Japanese firms shifted their strategy from imitative to innovative through their in-house 
policy to catch up with Western firms. However, as Japanese firms lacked the capacity to 
conform when consistency was low (e.g., inadequate resources such as talent, technology) to 
introduce innovation activities, they promoted R&D while entering alliances with foreign 
firms. The number of global New Molecular Entities (NCEs) discovered during 1975-89, was 
as follows: U.S. firms accounted for 47 NCEs, Western European firms 44 NCEs, and 
Japanese firms 5 NCEs22.
  Under the pressure of the Drug Price Policy and FDA from the 1990s, the R&D 
expenditure has increased year by year which has been a great burden for pharmaceutical 
companies23. The R&D strategy became open, firms began partnerships with companies, 
which had the skills they lack, in order to bring together experts and knowledge from 
different fields, through the methods of M&A, licensing-in, collaborative research, and 
clinical process out-sourcing. Pharmaceutical companies have therefore utilised external 
resources outside the company with the aims of modifying processes, shortening the R&D 
duration, and improving their core capacity. As regards the level of utilisation of external 
resources, however, there are big differences among Japanese companies, American 
companies, and European companies. That is, American and European companies utilise the 
external resources actively, whereas Japanese companies do not utilise them much (Xu, 
2018). The Japanese industry did become more R&D intensive, more dynamic and 
21　United States International Trade Commission, 1991: 8.
22　United States International Trade Commission, 1991: 9-8.
23 　The average time and cost to develop a new drug is an average of 10-15 years and $800 million to $2 
billion (Source: Website of PhRMA　http://www.phrma.org/sites/default/files/pdf/2014_PhRMA_
PROFILE.pdf Accessed Feb.3 2019).
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competitive—particularly with the entry of foreign firms. But whether it was the level of 
R&D investment or the size of firms, the Japanese scale remained smaller than that of 
global leaders. By raising the cost of R&D, firms have recently begun to make alliances not 
only with pharmaceutical companies but also with firm in other fields. Hence, incremental 
changes have altered the strategy from open-innovation to co-innovation because of financial 
factors.
4. Conclusion 
　The paper has tried to reveal the impact of external factors on intellectual property (IP) 
strategy by focusing on how institutional transitions matter for IP strategy from historical 
perspective. The paper focused on the case of Takeda, Eisai Co. Ltd., Daiichi Sankyo, 
Astellas to examine institutional transitions and IP strategies employed by pharmaceutical 
companies, and how institutions affect IP strategies.
　The finding suggests that institution factors have fundamental and incremental impacts 
on the strategies of pharmaceutical companies. Prior to the era of deregulation, Japan’s 
imitative and inefficient pharmaceutical firms had been sheltered by protectionist policies. 
Japanese firms were lagging behind in R&D research, due to delays in reforming the legal 
systems (refers to patent system and foreign investment regulation). Foreign investment 
regulation had protected domestic firms from overseas competition. Thus, delays in 
reforming this regulation delayed a firm entry to the global market and negatively affected 
weaker firms’ global competitiveness. Japanese firms attempted a large scale move towards 
internationally after changes in the patent system and foreign investment regulation. The 
presence of foreign investors, in particular, can create a motivation to operations. On the 
other hand, firms can gain competitive advantage by exploitation of strategic options. The 
changes in the patent system and foreign investment regulation mean that not only is the 
Japanese pharmaceutical market facing a globalisation wave but also firms are beginning to 
take a global view of their strategies. 
　Drug price policy and FDA regulation have increased the cost of R&D year-to-year. In 
order to respond to Drug price policy and FDA regulation, many strategies have been 
employed. IP strategy was developed from scale advantage perspective to resource-based 
perspective because of increasing R&D cost year after year under institutional pressures. 
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Firms engage in cross-border M&A, cooperating with competitors, which is considered as a 
strategic investment as well as an internalisation strategy, as it is a way to access external 
knowledge, finance, and international markets.
　Furthermore, the reason why Japanese companies have fallen behind Western companies 
is that Japanese companies delayed their shift to R&D-driven business model because of 
patent system and foreign investment regulation. Therefore, the paper proposes that 
external factors impact corporate operations and strategy, and especially, a protective legal 
context will lower the motivation to engage in corporate activities.
　This finding contributes to a better understanding of the influence of institutions on IP 
strategies on pharmaceutical industry. However, some limitation remains. Data constraints 
means this study could not fully analyse the causal relationship between overseas sales 
ratio, time periods and global operations. Despite these limitations, the finding suggests that 
fundamental change positively affects their global operation.    
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